328 related articles for article (PubMed ID: 36982933)
1. Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.
Król K; Mazur A; Stachyra-Strawa P; Grzybowska-Szatkowska L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982933
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Takamori S; Toyokawa G; Takada K; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Jan; 19(1):12-16. PubMed ID: 28739315
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
11. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
12. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
Sacco PC; Maione P; Guida C; Gridelli C
Curr Clin Pharmacol; 2017; 12(1):4-10. PubMed ID: 27908252
[TBL] [Abstract][Full Text] [Related]
13. Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer.
Zhou ZC; Chen KY; Li N; Xie MY; Sheng JM; Fan Y; Huang ZY
Thorac Cancer; 2022 Aug; 13(16):2291-2300. PubMed ID: 35762488
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
[TBL] [Abstract][Full Text] [Related]
15. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar R; Collins D; Dolly S; McDonald F; O'Brien MER; Yap TA
Curr Probl Cancer; 2017; 41(2):111-124. PubMed ID: 28214087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
